What is tirzepatide? Approved uses, evidence, and what 33 lab records reveal

What tirzepatide is

If you've been reading about weight-loss drugs, you've met tirzepatide as Zepbound or Mounjaro.

It's the one people describe as "the newer one," which is roughly right and misses what actually makes it different.

Semaglutide mimics one gut hormone. Tirzepatide mimics two.

It's a dual GIP and GLP-1 receptor agonist. GIP and GLP-1 are both hormones your gut releases after a meal. Both feed into how your body handles sugar and how full you feel.²

Our profile describes it as activating GIP and GLP-1 receptors, influencing glucose-dependent insulin secretion, appetite, caloric intake, and gastric emptying.

Whether hitting two receptors beats hitting one is a genuinely open question. The trial data doesn't settle it as cleanly as the marketing suggests.

What it definitely is: different pharmacology, not a stronger dose of the same idea.

What it's approved for

Tirzepatide is FDA approved, as specific products for specific named uses.¹

Zepbound and Mounjaro are separate approvals. Same molecule, different products, different indications.

One detail here mostly gets lost. The Zepbound label also covers moderate-to-severe obstructive sleep apnea in adults with obesity.

That's an unusual use for a metabolic drug. It came from a trial that measured sleep apnea directly, rather than guessing at it from weight change.

Our tirzepatide profile carries the regulatory detail and graded outcomes with their sources.

As always, an approval covers the finished product and the named use. Material sold "for research" inherits none of it.

How good is the evidence?

We rate tirzepatide high evidence with an established record, alongside semaglutide, liraglutide, and tesamorelin. Four compounds out of the twelve in our research directory reach that tier.

SURMOUNT-1 demonstrated substantial sustained weight reduction in adults with obesity, or overweight plus a weight-related complication.

The qualifiers matter as much as the headline. Adults with obesity, or overweight plus a complication. That's the population, and results belong to the population they were measured in.

What the evidence doesn't include is a clean answer to "is it better than semaglutide."

The two were mostly tested against placebo, not against each other. Comparing separate trials with different participants is unreliable, and we go through why in the side-by-side comparison.

What 33 lab records actually show

This is the part nobody else can publish, and the finding surprised us.

Our testing ledger holds 33 published lab records for tirzepatide, more than for any compound except retatrutide, each traceable to the original laboratory document.³

The common fear about research-market peptides is that they're fake or underdosed. The data says otherwise, and the real problem is different.

So the material is what it says it is, and it's clean. The label just isn't a reliable statement of how much is in the vial, and the error runs almost entirely in one direction.

A few examples, all above 99.6% pure:

Why "more than the label" isn't good news

It's tempting to read overfill as a bonus. It isn't.

A consistent bias in one direction is a signal about process, not generosity. Thirty-one out of 33 landing high points to something systematic: a filling convention that deliberately overshoots to guarantee the label minimum, or a measurement method that reads high, or both.

Analytical method matters here. A mass figure is a figure produced by one lab using one procedure, and procedures carry their own bias.⁴

We can't tell which from certificates alone, and we're not going to guess.

What we can say: the number printed on the vial is not the number in the vial. The gap is routinely double digits.

The same pattern shows up across our whole ledger, not just tirzepatide. Of 112 records carrying variance data, 98 measured over the label and 59 were 10% or more over.

For how to read one of these documents line by line, see our guide to certificates of analysis.

What it costs

Tirzepatide runs $34.00 to $180.00 across the two research vendors listing it, as of our 25 July 2026 check.

That's a 5x spread on two listings, which tells you those are different package sizes rather than different quality tiers. Our price market dates and separates every observation.

Prescription products sit in a different table entirely, because their access conditions aren't comparable.

Where tirzepatide sits

Genuinely well-evidenced molecule. Genuinely distinct pharmacology, not just a stronger GLP-1.

And a research-market supply where identity and purity hold up well. The dose on the label is off by a median of 13%, almost always high.

Good evidence about a molecule tells you nothing about what's in a specific vial. Tirzepatide is the compound where we finally have enough records to prove that those are two different questions.

Next: what semaglutide is, the two compared, or start with what peptides actually are.